oleoylethanolamide

Phase 2

MMedical University of South Carolina

oleoylethanolamide is one of 7 therapeutic programs targeting Alcohol Use Disorder (AUD). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Alcohol Use Disorder (AUD)Not yet recruiting

Alcohol Use Disorder (AUD)Phase 2

Not yet recruiting

Competition

Competitive Landscape

6 competitors in Alcohol Use Disorder (AUD)

#DrugCompanyPhaseTrials

Mounjaro

Eli Lilly

Phase 2

2 2

Intuniv

PPromius Pharma, LLC

Phase 2

1 3

Zonegran

AAzurity Pharmaceuticals

Phase 2

1 4

Pregnenolone

VVA Office of Research and Development

Phase 2

1 5

Psilocybin

COMPASS Pathways

Phase 2

1 6

Epidiolex

Jazz Pharmaceuticals

Preclinical

1 7

oleoylethanolamide

MMedical University of South Carolina

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2031

Phase 2Not yet recruiting

Alcohol Use Disorder (AUD)

NCT07503782

Clinical

Trials by Indication[1]

Alcohol Use Disorder (AUD)1 trial

Investigating Oleoylethanolamide (OEA) as a Novel Multi-System Based Therapeutic for Young Adults With Alcohol Use Disorder

Not yet recruiting·MMedical University of South Carolina·Phase 2·NCT07503782·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for oleoylethanolamide. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for oleoylethanolamide. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Medical University of South Carolina company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: MMedical University of South Carolina

oleoylethanolamide

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2031

Trials by Indication[1]

Alcohol Use Disorder (AUD)1 trial

References

Drug Info

Quick Facts

Related News